|
Immune Therapy Holdings AB or ITH is a Swedish biotechnology R&D holding company headquartered at the Karolinska Institutet and Karolinska University Hospital in Stockholm. ITH's research is primarily focused on its Tailored Leukapheresis (TLA) treatment for immune mediated inflammatory diseases (IMIDs).〔(ITH Introduction ) December 2012〕 == Tailored Leukapheresis treatment == Tailored Leukapheresis (TLA) treatment is an apheresis immunotherapy for selective removal of disease-causing pro-inflammatory cells extracorporeally, which has therapeutic application in various IMIDs that are caused and maintained by inflammation. TLA utilises the natural affinity of chemokines and chemokine receptors to selectively attract, bind, and deplete circulating pro-inflammatory cells ''en route'' to the site of inflammation. It is the first, and hitherto novel, apheresis technology with a demonstrated efficacy in targeting and removing selected leukocytes while leaving all other blood cells unaffected.〔(Clinical Immunology ) Volume 149, Issue 1, October 2013, Pages 73–82〕 The immunotherapy has been evaluated in a Phase I/II placebo-controlled clinical trial, where all primary and secondary clinical endpoints were met and the treatment showed an absence of any side effects of clinical significance.〔(ClinicalTrials.Gov ) 2010〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Immune Therapy Holdings」の詳細全文を読む スポンサード リンク
|